Iovance says ‘positive’ results from IOV-COM-202 trial published in abstract

Iovance Biotherapeutics announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online. Positive results from Cohort 1A in the IOV-COM-202 trial were published in an abstract and will be highlighted in an upcoming oral presentation at ASCO. Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naive to immune checkpoint inhibitor therapy. These results strongly support the ongoing Phase 3 TILVANCE-301 clinical trial. Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, “The compelling response rates, including a 30.4% complete response rate, and depth and durability of responses for lifileucel in combination with pembrolizumab strongly support our strategy in frontline advanced melanoma. Expanding TIL cell therapy into earlier treatment settings is a top priority for Iovance. The positive data are highly encouraging for the anticipated ORR results in our ongoing TILVANCE-301 trial. A planned early interim analysis of ORR, a dual primary endpoint in TILVANCE-301, may support an accelerated approval in the frontline setting, with full approval supported by progression free survival.”